A Retrospective and Prospective Study of a New Immunotherapy Regimen (MyVaccx) for Patients With Adenocarcinoma.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 27
- Locations
- 1
- Primary Endpoint
- MyVaccx immunotherapy treatment impact on late stage cancer disease
Study Overview
Brief Summary
A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 19 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Treatment with the MyVaccx System
- •Greater than 18 years of age
- •Signature of the informed consent
Exclusion Criteria
- •2 subjects treated with the MyVaccx System with known visceral disease
Arms & Interventions
Adenocarcinoma treated with MyVaccx
MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
Intervention: Immunotherapeutic Agents (Drug)
Adenocarcinoma treated with MyVaccx
MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
Intervention: Ablation (Device)
Outcomes
Primary Outcomes
MyVaccx immunotherapy treatment impact on late stage cancer disease
Time Frame: From date of treatment until the date of death from any cause up to 60 months
Time to death after the start of treatment
Secondary Outcomes
- MyVaccx immunotherapy treatment impact on late stage cancer disease(Time to progression after a complete or partial response up to 60 months)